Frontiers in Oncology (Jul 2024)

The safety and efficacy of the re-administration of gilteritinib in a patient with FLT3-mutated R/R AML with CNS relapse: a case report

  • Yueru Ji,
  • Zhuo Wan,
  • Jian Yang,
  • Miaowang Hao,
  • Li Liu,
  • Weiwei Qin

DOI
https://doi.org/10.3389/fonc.2024.1402970
Journal volume & issue
Vol. 14

Abstract

Read online

FLT3-ITD is a type of poor prognostic factors in acute myeloid leukemia (AML) disease. Gilteritinib, the second-generation FLT3 tyrosine kinase inhibitor, improved the overall survival of patients with relapsed/refractory FLT3-mutated AML in the ADMIRAL phase III trial. However, few data are available on the efficacy and safety of gilteritinib-based therapy for FLT3-mutated AML with central nervous system (CNS) involvement. We performed gilteritinib to treat a patient with CNS relapsed AML after allogeneic hematopoietic stem cell transplantation. The positive antileukemic effect of gilteritinib may bring new hope for the treatment of FLT3-mutated AML with CNS relapse.

Keywords